Drug intelligence / Profile preview

gotistobart

Development stage: Phase 3
Lead developer: OncoC4 and BioNTech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Gotistobart is a next-generation, pH-sensitive anti-CTLA-4 monoclonal antibody. It is designed to selectively deplete tumor-infiltrating regulatory T cells by preserving CTLA-4 recycling in peripheral tissues, aiming to enhance anti-tumor immunity while reducing immune-related adverse events. This mechanism differentiates it from other CTLA-4 inhibitors by potentially offering an improved therapeutic index. Gotistobart is being co-developed by BioNTech and OncoC4 for various oncology indications, with a primary focus on metastatic non-small cell lung cancer.

Brand names: gotistobart
Other names: 戈替妥巴

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on gotistobart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gotistobart.

Explore the full profile